Healthcare German Community

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).Read more

Fresenius Medical Care could benefit as more people need kidney treatment and care shifts toward easier options like home dialysis and newer in-clinic technology. But the outlook depends on whether it can lift patient volumes and profits while navigating changing healthcare rules and competition from new therapies.Read more

FamiCord is betting that placenta banking—an option many parents and doctors find easier to understand—can help more families choose long-term sample storage and lift what each customer spends. But the story hinges on overcoming falling birth rates, tough rules in key countries, and lingering skepticism after past failures in the industry.Read more

Siemens Healthineers leans into cutting-edge imaging and AI tools as hospitals move toward more digital, long-term partnerships that can smooth sales and lift profitability over time. The big question is whether tariffs, China pricing pressure, and currency swings derail that progress before the demand tailwinds from aging and chronic disease translate into steadier growth.Read more

Fresenius could benefit as more people need long-term care, while hospitals and dialysis clinics use digital tools to work faster and treat patients more smoothly. But rising costs, tighter healthcare budgets, and tougher competition in copycat medicines could make that growth harder to keep.Read more

Medios supplies hard-to-make specialty medicines in Germany, and a recent deal plus a push into advanced treatments could open the door to faster growth and wider reach across Europe than many expect. The big question is whether it can keep improving without stumbling on more deals, regulation changes, or expensive new projects.Read more

Stratec could get a lift as labs refresh older testing machines and push harder into automated, digital diagnostics that also drive repeat sales of supplies. But the story hinges on customers actually upgrading soon, while currency swings, tougher competition, and “buy local” pressure could hold back growth.Read more

Carl Zeiss Meditec is leaning into software, connected devices, and smarter eye-care tools just as demand rises in fast-growing markets and more treatments move to repeatable, service-like sales. But pricing pressure, fast-moving tech rivals, and trade tensions could squeeze profits and force the company to keep reinventing its products.Read more

Fresenius Medical Care looks like it’s quietly getting stronger as it cuts costs faster than expected and rolls out new dialysis technology that could win more patients in the U.S. The bigger story is whether aging, diabetes, and more at-home, tech-enabled care can lift growth for years—or whether staffing costs, new payment models, and fresh kidney-care alternatives squeeze profits.Read more